載入...
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...
Na minha lista:
| 發表在: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7352566/ https://ncbi.nlm.nih.gov/pubmed/32560564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12061607 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|